GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.

Key Details of the GRAIL ($GRAL) Class Action:

• Lead Plaintiff Deadline: August 4, 2026
• Alleged Misconduct: Securities fraud relating to GRAIL’s NHS-Galleri cancer trial
• Stock Drop: February 20, 2026 – 50.55% Stock Drop
• Court: U.S. District Court for the Northern District of California
• Action: Contact BFA Law to discuss your rights

Investors have until August 4, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GRAIL common stock. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned Robbins v. GRAIL, Inc., et al., No. 26-cv-05428.

Why is GRAIL Being Sued for Securities Fraud?

GRAIL is a commercial-stage healthcare company focused on early cancer detection. GRAIL developed Galleri, a multi-cancer early detection test that analyzes blood samples to screen for multiple cancers, identify the likely organ or tissue of origin, and assist in the screening process. As part of GRAIL’s efforts to attain an accelerated implementation of its test as a national screening program through the United Kingdom’s National Health Service (“NHS”), GRAIL conducted the “NHS-Galleri trial.” The primary objective of the NHS-Galleri trial was “to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not.”

According to the complaint, during the relevant period, GRAIL made positive statements about Galleri, the NHS-Galleri trial design, and top-line results from the first screening round, including that the NHS-Galleri trial was “designed with three consecutive years of screening in order to achieve the primary endpoint,” and that “Galleri is working in the real world.”

As alleged, in truth, the NHS-Galleri trial’s three-year timeframe was insufficient to demonstrate the primary endpoint.

Why did GRAIL’s Stock Drop?

On February 19, 2026, GRAIL announced top-line results from its NHS-Galleri trial. Although the Company emphasized certain favorable results, GRAIL disclosed that the trial did not meet its primary endpoint. Specifically, GRAIL stated that the “primary endpoint of statistically significant Stage III-IV reduction was not observed.” GRAIL attributed the disappointing outcome, in part, to “probably need[ing] a longer follow-up time to be able to [compare the two arms of the study] adequately.”

Schreibe Deinen Kommentar